Index of drugs

Supportive treatment and prevention of recurrent bleeding from gastric and duodenal ulcer. Prevention of stress ulcer mucous membrane of the upper gastrointestinal tract. Prevention of aspiration with acid gastric contents (Mendelson's syndrome) before general anesthesia of patients at risk.Children from 6 months up to 12 years. Short-term treatment of peptic ulcer of the stomach or duodenum. Treatment of gastroesophageal reflux (including reflux oesophagitis) and alleviation of gastroesophageal reflux disease.

1 ampoule (5 ml) contains 50 mg ranitidine.

Competitive antagonist of the histamine H receptor₂ in the gastric mucosa, inhibiting the secretion of hydrochloric acid by the parietal cells and to a lesser extent pepsin and gastric juice. Ranitidine inhibits secretion in both resting and stimulated phases of food, histamine, Caffeine, insulin, cholinomimetics, gastrin and pentagastrin. It strongly inhibits nocturnal secretion. The effect of a single 50 mg dose is maintained for 6 hours. T_0,5 is 2 hours. It is excreted by the kidneys, mainly unchanged (about 70%) and partly as metabolites.

Hypersensitivity to ranitidine or other ingredients of the preparation.

Avoid use in patients with a history of porphyria (the risk of acute attacks). Before starting treatment in patients with peptic ulcer, the neoplastic nature of the disease should be excluded, as treatment with ranitidine may mask the symptoms of cancer. Caution should be used in patients with impaired renal function (dose modification recommended). Strictly adhere to the prescribed rate of administration, because rapid administration of ranitidine may cause bradycardia, especially in patients with predisposition to arrhythmias. In the prevention of stress ulcer, the drug is used intravenously, after considering the benefit / risk ratio, only in patients in whom damage to the mucous membrane may cause serious complications. In elderly patients with chronic lung disease, diabetes or reduced immunity, there is an increased risk of outpatient pneumonia.

The preparation can be used during pregnancy and breastfeeding only when definitely needed.

Uncommon: abdominal pain, constipation, nausea. Rarely: hypersensitivity reactions (urticaria, angioneurotic edema, fever, bronchospasm, hypotension, chest pain), skin rash, increase in serum creatinine. Very rare: usually transient leucopenia and thrombocytopenia, agranulocytosis or pancytopenia, aplastic anemia, sometimes with hypoplasia or bone marrow aplasia, anaphylactic shock, transient confusion, depression and hallucinations, severe headache, dizziness, transient involuntary movements, transient visual disturbances, tachycardia, bradycardia, atrio-ventricular block, asystole, vasculitis, acute pancreatitis, diarrhea, hepatitis (cellular, tubular or mixed) with jaundice or without jaundice, erythema multiforme, alopecia, joint pain, myalgia, acute interstitial nephritis, transient impotence, gynecomastia and mlekotok. In addition, with an unknown frequency: dyspnoea.

Intravenously.Adults and youth from 12 y. Supportive treatment and prevention of recurrent bleeding from gastric and duodenal ulcer: 50 mg (1 amp.) By slow intravenous injection; This dose can be repeated 3 or 4 times a day (every 6 or 8 hours), given by slow intravenous injection or by intravenous infusion.Prevention of bleeding from the upper gastrointestinal tract from stress ulcer in especially seriously ill patients: 50 mg by slow intravenous injection followed by continuous intravenous infusion at a dose of 0.125 mg-0.250 mg / kg / h.Preventing Mendelson's team: 50 mg once in a slow intravenous injection for 45-60 minutes before entering the general anesthesia.Children from 6 months up to 12 years. Administer in a slow intravenous injection up to a maximum dose of 50 mg every 6-8 hours.Short-term treatment of peptic ulcer and gastro-oesophageal reflux. Intravenous administration to children indicated only when oral treatment is not possible. In children, the drug is administered in doses that are effective in treating these diseases in adult patients and that effectively inhibit the secretion of hydrochloric acid in critically ill children. The initial dose (2.0 or 2.5 mg / kg, maximum 50 mg) can be given in a slow,> 10-minute intravenous infusion (via a syringe pump) followed by 5 ml of saline for 5 min, or after dilution with physiological saline up to 20 ml. The pH value> 4.0 of the gastric content can be maintained by administering ranitidine infusion at a dose of 1.5 mg / kg. every 6-8 h. Alternatively, the treatment can be carried out continuously: after a loading dose of 0.45 mg / kg. ranitidine is given as a continuous infusion at a rate of 0.15 mg / kg / h.Prevention of stress ulcer in seriously ill patients: 1 mg / kg (maximum 50 mg) every 6-8 hours; alternative continuous treatment: 0.125-0.250 mg / kg / h in continuous infusion.Special groups of patients. Renal failure - CCr> 50 ml / min: single dose 50 mg, daily 150-200 mg .; CCr <50 ml / min: single dose 25 mg, daily 75-100 mg. Dialyzed patients should be given the above-mentioned doses after dialysis.Way of giving. Before administration, the drug should be diluted according to the manufacturer's instructions. Administer in a slow intravenous injection (at least 2 min), short intravenous infusion (for 2 hours at 25 mg / h) or a long-term intravenous infusion (initially for 3 min intravenously - 50 mg, then at a rate of 0.125-0.250 mg / kg hr). Do not mix with infusion fluids containing fructose or with other medications containing fluids.